Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBITDA: 2014-2025

Historic EBITDA for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$1.8 million.

  • Ascendis Pharma A's EBITDA fell 1188.00% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.7 million, marking a year-over-year increase of 53.89%. This contributed to the annual value of -$408.1 million for FY2024, which is 21.67% up from last year.
  • Per Ascendis Pharma A's latest filing, its EBITDA stood at -$1.8 million for Q3 2025, which was down 16.20% from -$1.6 million recorded in Q2 2025.
  • Ascendis Pharma A's EBITDA's 5-year high stood at $621,585 during Q3 2023, with a 5-year trough of -$209.4 million in Q4 2022.
  • Over the past 3 years, Ascendis Pharma A's median EBITDA value was -$844,720 (recorded in 2023), while the average stood at -$12.7 million.
  • Per our database at Business Quant, Ascendis Pharma A's EBITDA soared by 108.10% in 2024 and then plummeted by 9,903.63% in 2025.
  • Over the past 5 years, Ascendis Pharma A's EBITDA (Quarterly) stood at -$120.1 million in 2021, then plummeted by 74.32% to -$209.4 million in 2022, then spiked by 54.58% to -$95.1 million in 2023, then soared by 57.70% to -$40.2 million in 2024, then slumped by 1,188.00% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, -$1.6 million for Q2 2025, and -$78,891 during Q1 2025.